- cafead   Oct 24, 2022 at 10:52: AM
via Novartis has chalked up another clinical trial win for its targeted factor B inhibitor iptacopan as it strives to position the drug as a patient-friendly, oral alternative to big-selling injectable rivals.
article source
article source